# A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects

> **NCT02211469** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 41 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** BMS-986104
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02211469
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2015-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02211469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02211469, "A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02211469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*